Stock Market News

Regeneron Pharma (REGN) News

1 week Regeneron Reports Eylea Sales, Provides Other Pipeline Updates Zacks

1 week Regeneron Pharmaceuticals, Inc. (REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript) Seeking Alpha

2 weeks Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold? Zacks

2 weeks Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again Zacks

1 month REGN’s Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study Zacks

1 month Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains Zacks

1 month Regeneron Down 15.5% Year to Date: How to Play the Stock? Zacks

2 months Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript) Seeking Alpha

2 months Do Options Traders Know Something About Regeneron (REGN) Stock We Don’t? Zacks

2 months Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript) Seeking Alpha

2 months FDA Accepts SNY and REGN’s Dupixent Re-Submitted sBLA for Urticaria Zacks

3 months Regeneron Pharma earnings beat by $0.74, revenue topped estimates Investing.com

3 months Regeneron to Report Q3 Earnings: What’s in the Offing? Zacks

3 months Brighton Jones LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) MarketBeat

3 months Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Silver Oak Securities Incorporated MarketBeat

3 months Regeneron Pharmaceuticals (NASDAQ:REGN) Receives “Neutral” Rating from Cantor Fitzgerald MarketBeat

3 months Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,080.00 at Barclays MarketBeat

3 months Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,050.00 by Analysts at Wells Fargo & Company MarketBeat

3 months Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Outperform” Rating from Royal Bank of Canada MarketBeat

3 months Creative Planning Purchases 2,178 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) MarketBeat

3 months Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Raymond James & Associates MarketBeat